These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22192883)

  • 1. Targeting the S and G2 checkpoint to treat cancer.
    Chen T; Stephens PA; Middleton FK; Curtin NJ
    Drug Discov Today; 2012 Mar; 17(5-6):194-202. PubMed ID: 22192883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy.
    Anderson HJ; Andersen RJ; Roberge M
    Prog Cell Cycle Res; 2003; 5():423-30. PubMed ID: 14593736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints.
    Kohn EA; Yoo CJ; Eastman A
    Cancer Res; 2003 Jan; 63(1):31-5. PubMed ID: 12517773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cell cycle regulation after exposure to ionizing radiation].
    Teyssier F; Bay JO; Dionet C; Verrelle P
    Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.
    Ashwell S; Zabludoff S
    Clin Cancer Res; 2008 Jul; 14(13):4032-7. PubMed ID: 18593978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
    King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
    Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical strategies for development of ATR inhibitors.
    Llona-Minguez S; Höglund A; Jacques SA; Koolmeister T; Helleday T
    Expert Rev Mol Med; 2014 May; 16():e10. PubMed ID: 24810715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.
    Bucher N; Britten CD
    Br J Cancer; 2008 Feb; 98(3):523-8. PubMed ID: 18231106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A UVR-induced G2-phase checkpoint response to ssDNA gaps produced by replication fork bypass of unrepaired lesions is defective in melanoma.
    Wigan M; Pinder A; Giles N; Pavey S; Burgess A; Wong S; Sturm RA; Gabrielli B
    J Invest Dermatol; 2012 Jun; 132(6):1681-8. PubMed ID: 22402442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Checkpoint to Kill Cancer Cells.
    Benada J; Macurek L
    Biomolecules; 2015 Aug; 5(3):1912-37. PubMed ID: 26295265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeine induces S-phase apoptosis in cis-diamminedichloroplatinum-treated cells, whereas cis-diamminedichloroplatinum induces a block in G2/M.
    Shinomiya N; Takemura T; Iwamoto K; Rokutanda M
    Cytometry; 1997 Apr; 27(4):365-73. PubMed ID: 9098629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs.
    Blagosklonny MV
    Oncogene; 2002 Sep; 21(41):6249-54. PubMed ID: 12214265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells.
    Bhuyan BK; Smith KS; Adams EG; Petzold GL; McGovren JP
    Cancer Res; 1992 Oct; 52(20):5687-92. PubMed ID: 1394193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
    Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
    Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
    Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
    Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.
    Blasina A; Hallin J; Chen E; Arango ME; Kraynov E; Register J; Grant S; Ninkovic S; Chen P; Nichols T; O'Connor P; Anderes K
    Mol Cancer Ther; 2008 Aug; 7(8):2394-404. PubMed ID: 18723486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma.
    Barnaba N; LaRocque JR
    Cell Cycle; 2021 Jun; 20(11):1041-1051. PubMed ID: 33966611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G2 checkpoint abrogators as anticancer drugs.
    Kawabe T
    Mol Cancer Ther; 2004 Apr; 3(4):513-9. PubMed ID: 15078995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Specific S/G
    Hoffman RM; Yano S
    Methods Mol Biol; 2019; 1866():49-60. PubMed ID: 30725407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.